Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05354050 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of DARE-BV1
A Phase 1 study, sponsored by Daré Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05354050 is a Phase 1 study that has completed, run by Daré Bioscience. The registered enrollment target is 21 participants.
The verdict
NCT05354050, a Phase 1 study, has completed, sponsored by Daré Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).
Interventions
- DRUG DARE-BV1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2020-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05354050
The ClinicalTrials.gov registry entry for NCT05354050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daré Bioscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DARE-BV1 is the first listed.
NCT05354050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05354050 about?
NCT05354050 is a clinical study titled "Pharmacokinetic Study of DARE-BV1". Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).
What is the current status of trial NCT05354050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-11-03. Estimated completion is 2020-12-02.
What interventions are being tested in trial NCT05354050?
The interventions under investigation include: DARE-BV1 (DRUG).
Who is sponsoring clinical trial NCT05354050?
This trial is sponsored by Daré Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.